Torsemide as a Primary Choice in Edema Associated with Heart Failure.
Journal
The Journal of the Association of Physicians of India
ISSN: 0004-5772
Titre abrégé: J Assoc Physicians India
Pays: India
ID NLM: 7505585
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
18
9
2024
Statut:
ppublish
Résumé
Heart failure (HF) is the fastest-growing disease with a higher fatality rate. The most differentiating feature of HF is pulmonary or peripheral edema, which is characterized by a gradient between intravascular and extravascular pressure. Loop diuretics were chosen as the primary treatment for edema associated with HF due to their efficacy and early onset of action. If an oral dose had not been provided, intravenous (IV) administration of torsemide, or equal doses of furosemide and bumetanide, was preferred. However, the key variables for selecting and administering loop diuretics are their pharmacological qualities as well as their clinical efficacy. Torsemide has greater bioavailability, a higher rate of absorption, a longer duration of action, and lesser ototoxicity, making it the primary choice in the management of edematous HF.
Identifiants
pubmed: 39291568
doi: 10.59556/japi.72.0672
doi:
Substances chimiques
Torsemide
W31X2H97FB
Sodium Potassium Chloride Symporter Inhibitors
0
Diuretics
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-23Informations de copyright
© Journal of the Association of Physicians of India 2024.